Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …

Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …

Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where
they present peptides to T cells, which gives them a key role in the development of T-cell …

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing
with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However …

Computational prediction of the peptides presented on major histocompatibility complex
(MHC) class I proteins is an important tool for studying T cell immunity. The data available to …

Human leukocyte antigen (HLA) can recognize and bind foreign peptides to present them to
specialized immune cells, then initiate an immune response. Computational prediction of the …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …